Arcellx Inc (ACLX)

Currency in USD
115.07
+0.04(+0.03%)
Closed·
Showing Arcellx historical data. For real-time data please try another search
Fair Value
Day's Range
114.99115.13
52 wk Range
47.86115.13
Key Statistics
Prev. Close
115.07
Open
115.04
Day's Range
114.99-115.13
52 wk Range
47.86-115.13
Volume
14.67M
Average Volume (3m)
2.43M
1-Year Change
77.8241%
Book Value / Share
6.96
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ACLX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
112.85
Downside
-1.93%
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.

Arcellx Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Analyst Ratings

0 Buy
17 Hold
0 Sell
Ratings:
17 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 112.85
(-1.93% Downside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Arcellx Inc SWOT Analysis


Promising Myeloma Therapy
Arcellx's anito-cel shows potential best-in-class efficacy and safety in multiple myeloma treatment, with 97% overall response rate in clinical trials
Market Disruption Ahead
Analysts project CAR-T therapies could capture 30% of multiple myeloma market, positioning Arcellx for significant growth in a competitive landscape
Financial Horizon
Despite current losses, Arcellx maintains strong liquidity. Analysts forecast EPS of -$1.47 for FY 2023, -$1.53 for FY 2024, and -$4.27 for FY 2025
Bullish Outlook
Analysts maintain strong buy consensus with high target of $134. Barclays and Canaccord set price targets at $115 and $121, respectively
Read full SWOT analysis

Earnings

Latest Release
Feb 26, 2026
EPS / Forecast
-1.04 / -1.03
Revenue / Forecast
3.68M / 12.52M
EPS Revisions
Last 90 days

ACLX Income Statement

Compare ACLX to Peers and Sector

Metrics to compare
ACLX
Peers
Sector
Relationship
P/E Ratio
−29.5x0.0x−0.5x
PEG Ratio
0.290.000.00
Price/Book
16.8x0.0x2.6x
Price / LTM Sales
302.9x0.0x3.2x
Upside (Analyst Target)
−0.1%0.0%47.8%
Fair Value Upside
Unlock0.0%5.9%Unlock

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company’s lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company preclinical product includes ACLX-004 for the treatment of AML and MDS. Further, the company focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize nito-cel and next-generation autologous and non-autologous CAR-T cell therapy products. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. As of April 28, 2026, Arcellx, Inc. operates as a subsidiary of Gilead Sciences, Inc.

People Also Watch

24.20
TNGX
+6.56%
141.69
CELC
-2.27%
9.990
ERAS
-1.48%
90.24
DNTH
+1.01%
67.18
CGON
-0.78%
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.